vs

Side-by-side financial comparison of AvePoint, Inc. (AVPT) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

AvePoint, Inc. is the larger business by last-quarter revenue ($114.7M vs $83.1M, roughly 1.4× PROCEPT BioRobotics Corp). AvePoint, Inc. runs the higher net margin — 13.6% vs -38.1%, a 51.7% gap on every dollar of revenue. On growth, AvePoint, Inc. posted the faster year-over-year revenue change (28.6% vs 20.2%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 24.0%).

AvePoint is a public company headquartered in Jersey City, New Jersey, United States. It develops software products intended to add features or security to other major platforms, like Microsoft 365, Google, or Salesforce. AvePoint was founded in 2001 and went public on NASDAQ in 2020.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

AVPT vs PRCT — Head-to-Head

Bigger by revenue
AVPT
AVPT
1.4× larger
AVPT
$114.7M
$83.1M
PRCT
Growing faster (revenue YoY)
AVPT
AVPT
+8.4% gap
AVPT
28.6%
20.2%
PRCT
Higher net margin
AVPT
AVPT
51.7% more per $
AVPT
13.6%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
24.0%
AVPT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AVPT
AVPT
PRCT
PRCT
Revenue
$114.7M
$83.1M
Net Profit
$15.6M
$-31.6M
Gross Margin
73.6%
64.9%
Operating Margin
12.7%
-4.1%
Net Margin
13.6%
-38.1%
Revenue YoY
28.6%
20.2%
Net Profit YoY
191.1%
-27.9%
EPS (diluted)
$0.06
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVPT
AVPT
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$114.7M
$76.4M
Q3 25
$109.7M
$83.3M
Q2 25
$102.0M
$79.2M
Q1 25
$93.1M
$69.2M
Q4 24
$89.2M
$68.2M
Q3 24
$88.8M
$58.4M
Q2 24
$78.0M
$53.4M
Net Profit
AVPT
AVPT
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$15.6M
$-29.8M
Q3 25
$13.0M
$-21.4M
Q2 25
$2.9M
$-19.6M
Q1 25
$3.6M
$-24.7M
Q4 24
$-17.2M
$-18.9M
Q3 24
$2.6M
$-21.0M
Q2 24
$-12.9M
$-25.6M
Gross Margin
AVPT
AVPT
PRCT
PRCT
Q1 26
64.9%
Q4 25
73.6%
60.6%
Q3 25
74.4%
64.8%
Q2 25
74.0%
65.4%
Q1 25
74.3%
63.9%
Q4 24
75.4%
64.0%
Q3 24
76.1%
63.2%
Q2 24
75.7%
59.0%
Operating Margin
AVPT
AVPT
PRCT
PRCT
Q1 26
-4.1%
Q4 25
12.7%
-40.6%
Q3 25
7.4%
-27.8%
Q2 25
7.0%
-28.0%
Q1 25
3.5%
-39.7%
Q4 24
5.4%
-28.9%
Q3 24
8.6%
-38.4%
Q2 24
-2.7%
-50.3%
Net Margin
AVPT
AVPT
PRCT
PRCT
Q1 26
-38.1%
Q4 25
13.6%
-39.1%
Q3 25
11.9%
-25.7%
Q2 25
2.8%
-24.7%
Q1 25
3.8%
-35.8%
Q4 24
-19.3%
-27.6%
Q3 24
3.0%
-35.9%
Q2 24
-16.6%
-48.0%
EPS (diluted)
AVPT
AVPT
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.06
$-0.54
Q3 25
$0.06
$-0.38
Q2 25
$0.01
$-0.35
Q1 25
$0.02
$-0.45
Q4 24
$-0.09
$-0.34
Q3 24
$0.01
$-0.40
Q2 24
$-0.07
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVPT
AVPT
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$481.1M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$478.7M
$347.7M
Total Assets
$789.2M
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVPT
AVPT
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$481.1M
$286.5M
Q3 25
$471.6M
$294.3M
Q2 25
$430.1M
$302.7M
Q1 25
$351.8M
$316.2M
Q4 24
$290.9M
$333.7M
Q3 24
$250.0M
$196.8M
Q2 24
$230.8M
$214.1M
Total Debt
AVPT
AVPT
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
AVPT
AVPT
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$478.7M
$365.9M
Q3 25
$466.8M
$380.3M
Q2 25
$443.1M
$385.8M
Q1 25
$361.5M
$389.2M
Q4 24
$270.9M
$402.2M
Q3 24
$215.7M
$241.2M
Q2 24
$207.4M
$251.8M
Total Assets
AVPT
AVPT
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$789.2M
$508.1M
Q3 25
$743.5M
$511.5M
Q2 25
$700.1M
$513.1M
Q1 25
$598.8M
$519.4M
Q4 24
$519.1M
$534.0M
Q3 24
$463.0M
$374.1M
Q2 24
$427.3M
$374.4M
Debt / Equity
AVPT
AVPT
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVPT
AVPT
PRCT
PRCT
Operating Cash FlowLast quarter
$29.7M
Free Cash FlowOCF − Capex
$29.0M
FCF MarginFCF / Revenue
25.3%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
1.90×
TTM Free Cash FlowTrailing 4 quarters
$81.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVPT
AVPT
PRCT
PRCT
Q1 26
Q4 25
$29.7M
$-10.3M
Q3 25
$34.8M
$-6.6M
Q2 25
$20.3M
$-15.0M
Q1 25
$495.0K
$-17.0M
Q4 24
$32.8M
$-32.4M
Q3 24
$32.2M
$-18.8M
Q2 24
$16.2M
$-15.7M
Free Cash Flow
AVPT
AVPT
PRCT
PRCT
Q1 26
Q4 25
$29.0M
$-12.2M
Q3 25
$34.3M
$-9.5M
Q2 25
$19.3M
$-17.8M
Q1 25
$-1.0M
$-18.8M
Q4 24
$32.0M
$-33.6M
Q3 24
$30.8M
$-19.0M
Q2 24
$15.8M
$-16.8M
FCF Margin
AVPT
AVPT
PRCT
PRCT
Q1 26
Q4 25
25.3%
-15.9%
Q3 25
31.3%
-11.4%
Q2 25
18.9%
-22.5%
Q1 25
-1.1%
-27.2%
Q4 24
35.9%
-49.2%
Q3 24
34.7%
-32.6%
Q2 24
20.2%
-31.4%
Capex Intensity
AVPT
AVPT
PRCT
PRCT
Q1 26
Q4 25
0.6%
2.4%
Q3 25
0.5%
3.4%
Q2 25
0.9%
3.5%
Q1 25
1.6%
2.7%
Q4 24
0.8%
1.7%
Q3 24
1.6%
0.4%
Q2 24
0.5%
2.0%
Cash Conversion
AVPT
AVPT
PRCT
PRCT
Q1 26
Q4 25
1.90×
Q3 25
2.68×
Q2 25
7.01×
Q1 25
0.14×
Q4 24
Q3 24
12.30×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVPT
AVPT

SAAS$88.9M78%
Services$14.7M13%
Termed License And Support$10.1M9%

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons